{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T01:33:27Z","timestamp":1771983207289,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhandsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Hand Surgery"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jhsa.2020.07.009","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T02:18:04Z","timestamp":1600222684000},"page":"54-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Botulinum Toxin for the Treatment of Intractable Raynaud Phenomenon"],"prefix":"10.1016","volume":"46","author":[{"given":"Jose E.","family":"Gallegos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani C.","family":"Inglesby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary T.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando A.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jhsa.2020.07.009_bib1","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.jhsa.2010.09.019","article-title":"Botulinum toxin type a in the treatment of Raynaud's phenomenon","volume":"35","author":"Neumeister","year":"2010","journal-title":"J\u00a0Hand Surg Am"},{"issue":"1","key":"10.1016\/j.jhsa.2020.07.009_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.hcl.2014.09.011","article-title":"Role and rationale for extended periarterial sympathectomy in the management of severe Raynaud syndrome: techniques and results","volume":"31","author":"Merritt","year":"2015","journal-title":"Hand Clin"},{"issue":"7","key":"10.1016\/j.jhsa.2020.07.009_bib3","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s10072-015-2084-6","article-title":"Treatment of Raynaud's phenomenon with botulinum toxin type A","volume":"36","author":"Zhang","year":"2015","journal-title":"Neurol Sci"},{"issue":"1","key":"10.1016\/j.jhsa.2020.07.009_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/PRS.0b013e3181a80576","article-title":"Botox therapy for ischemic digits","volume":"124","author":"Neumeister","year":"2009","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"10.1016\/j.jhsa.2020.07.009_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hcl.2014.09.003","article-title":"The role of botulinum toxin in vasospastic disorders of the hand","volume":"31","author":"Neumeister","year":"2015","journal-title":"Hand Clin"},{"issue":"6","key":"10.1016\/j.jhsa.2020.07.009_bib6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0363-5023(80)80104-3","article-title":"Digital artery sympathectomy","volume":"5","author":"Flatt","year":"1980","journal-title":"J\u00a0Hand Surg Am"},{"issue":"8","key":"10.1016\/j.jhsa.2020.07.009_bib7","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/art.40123","article-title":"The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial","volume":"69","author":"Bello","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.jhsa.2020.07.009_bib8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhsa.2008.11.026","article-title":"Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon","volume":"34","author":"Fregene","year":"2009","journal-title":"J\u00a0Hand Surg Am"},{"issue":"1","key":"10.1016\/j.jhsa.2020.07.009_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/1346-8138.13030","article-title":"Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study","volume":"43","author":"Motegi","year":"2016","journal-title":"J\u00a0Dermatol"},{"issue":"7","key":"10.1016\/j.jhsa.2020.07.009_bib10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2340\/00015555-2665","article-title":"Efficacy of botulinum toxin Bb injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis","volume":"97","author":"Motegi","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.jhsa.2020.07.009_bib11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.anplas.2011.11.001","article-title":"Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis [in French]","volume":"58","author":"Serri","year":"2013","journal-title":"Ann Chir Plast Esthet"},{"issue":"4","key":"10.1016\/j.jhsa.2020.07.009_bib12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2362.2004.01324.x","article-title":"Botulinum toxin in the treatment of Raynaud\u2019s phenomenon: a pilot study","volume":"34","author":"Sycha","year":"2003","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.jhsa.2020.07.009_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/01.prs.0000244860.00674.57","article-title":"Management of vasospastic disorders with botulinum toxin A","volume":"119","author":"Van Beek","year":"2007","journal-title":"Plast Reconstr Surg"},{"issue":"40","key":"10.1016\/j.jhsa.2020.07.009_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005092","article-title":"A\u00a0case report of the beneficial effects of botulinum toxin type A on Raynaud phenomenon in a patient with lung cancer","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.jhsa.2020.07.009_bib15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.semarthrit.2011.07.006","article-title":"Botulinum toxin A treatment of Raynaud's phenomenon: a review","volume":"41","author":"Iorio","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jhsa.2020.07.009_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13555-013-0033-y","article-title":"Triple-blind, prospective, internally controlled comparative study between abobotulinumtoxin A and onabotulinumtoxin A for the treatment of facial rhytids","volume":"3","author":"Kassir","year":"2013","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jhsa.2020.07.009_bib17","series-title":"Botox [package insert]","year":"2017"},{"key":"10.1016\/j.jhsa.2020.07.009_bib18","series-title":"Inc. Dysport [package insert]","year":"2015"},{"issue":"7","key":"10.1016\/j.jhsa.2020.07.009_bib19","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10072-013-1357-1","article-title":"Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence","volume":"34","author":"Ravenni","year":"2013","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jhsa.2020.07.009_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.12659\/MSMBR.893998","article-title":"How can follow-up of patients with Raynaud phenomenon be optimized?","volume":"21","author":"Kadan","year":"2015","journal-title":"Med Sci Monit Basic Res"}],"container-title":["The Journal of Hand Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0363502320304068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0363502320304068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T22:59:10Z","timestamp":1759791550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0363502320304068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0363502320304068"],"URL":"https:\/\/doi.org\/10.1016\/j.jhsa.2020.07.009","relation":{},"ISSN":["0363-5023"],"issn-type":[{"value":"0363-5023","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Botulinum Toxin for the Treatment of Intractable Raynaud Phenomenon","name":"articletitle","label":"Article Title"},{"value":"The Journal of Hand Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhsa.2020.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Society for Surgery of the Hand. All rights reserved.","name":"copyright","label":"Copyright"}]}}